Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). 2014

Evangelia Tantalaki, and Christina Piperi, and Sarantis Livadas, and Anastasios Kollias, and Christos Adamopoulos, and Aikaterini Koulouri, and Charikleia Christakou, and Evanthia Diamanti-Kandarakis
Endocrine Unit, Third Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Greece.

OBJECTIVE To investigate the impact of dietary intervention on Advanced Glycation End products (AGEs) intake on the hormonal and metabolic profile in women with polycystic ovary syndrome (PCOS). METHODS After baseline evaluation, 23 women with PCOS [mean ± SD, age: 23.4 ± 5.7 years; body mass index (BMI): 26 ± 5.7 kg/m2] underwent the following consecutive 2-month dietary regimens: a hypocaloric diet with ad-libitum AGEs content (Hypo), an isocaloric diet with high AGEs (HA) and an isocaloric diet with low AGEs (LA). Metabolic, hormonal and oxidative stress status was assessed and AGEs levels were determined in all subjects after the completion of each dietary intervention. RESULTS Serum levels of AGEs, testosterone, oxidative stress, insulin and HOMA-IR index were significantly increased on the HA compared to the Hypo diet and subsequently decreased on the LA diet (compared to HA) (p<0.05 for all parameters). BMI remained unaltered throughout the HA and LA periods compared to the Hypo period. Serum AGEs were strongly correlated with insulin, as well as with HOMA, during the LA dietary period (r=0.53, p=0.02 and r=0.51, p=0.03, respectively). For the same period, dietary AGEs were correlated with insulin levels (rho=0.49, p=0.04). CONCLUSIONS Modifications of dietary AGEs intake are associated with parallel changes in serum AGEs, metabolic, hormonal and oxidative stress biomarkers in women with PCOS. These novel findings support recommendations for a low AGEs dietary content along with lifestyle changes in women with PCOS.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D011085 Polycystic Ovary Syndrome A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading. Stein-Leventhal Syndrome,Polycystic Ovarian Syndrome,Polycystic Ovary Syndrome 1,Sclerocystic Ovarian Degeneration,Sclerocystic Ovaries,Sclerocystic Ovary Syndrome,Ovarian Degeneration, Sclerocystic,Ovarian Syndrome, Polycystic,Ovary Syndrome, Polycystic,Ovary, Sclerocystic,Sclerocystic Ovary,Stein Leventhal Syndrome,Syndrome, Polycystic Ovary,Syndrome, Stein-Leventhal
D004038 Diet, Reducing A diet designed to cause an individual to lose weight. Weight Loss Diet,Weight Reduction Diet,Diet, Weight Loss,Diet, Weight Reduction,Diets, Reducing,Diets, Weight Loss,Diets, Weight Reduction,Reducing Diet,Reducing Diets,Weight Loss Diets,Weight Reduction Diets
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013739 Testosterone A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL. 17-beta-Hydroxy-4-Androsten-3-one,17-beta-Hydroxy-8 alpha-4-Androsten-3-one,8-Isotestosterone,AndroGel,Androderm,Andropatch,Androtop,Histerone,Sterotate,Sustanon,Testim,Testoderm,Testolin,Testopel,Testosterone Sulfate,17 beta Hydroxy 4 Androsten 3 one,17 beta Hydroxy 8 alpha 4 Androsten 3 one,8 Isotestosterone
D017127 Glycation End Products, Advanced A heterogeneous group of compounds derived from rearrangements, oxidation, and cross-linking reactions that follow from non-enzymatic glycation of amino groups in PROTEINS; LIPIDS; or NUCLEIC ACIDS. Their accumulation in vivo accelerates under hyperglycemic, oxidative, or inflammatory conditions. Heat also accelerates the formation of advanced glycation end products (AGEs) such seen with the browning of food during cooking. Advanced Glycation End Product,Advanced Glycation Endproduct,Advanced Maillard Reaction End Product,Glycated Lipids,Glycotoxins,Maillard Product,Maillard Reaction End Product,Maillard Reaction Product,Advanced Glycation End Products,Advanced Glycation Endproducts,Advanced Maillard Reaction End Products,Glycation Endproducts, Advanced,Maillard Products,Maillard Reaction End Products,Maillard Reaction Products,Glycation Endproduct, Advanced,Lipids, Glycated,Product, Maillard Reaction,Products, Maillard,Products, Maillard Reaction,Reaction Products, Maillard

Related Publications

Evangelia Tantalaki, and Christina Piperi, and Sarantis Livadas, and Anastasios Kollias, and Christos Adamopoulos, and Aikaterini Koulouri, and Charikleia Christakou, and Evanthia Diamanti-Kandarakis
January 2016, Current pharmaceutical design,
Evangelia Tantalaki, and Christina Piperi, and Sarantis Livadas, and Anastasios Kollias, and Christos Adamopoulos, and Aikaterini Koulouri, and Charikleia Christakou, and Evanthia Diamanti-Kandarakis
October 2008, Clinical endocrinology,
Evangelia Tantalaki, and Christina Piperi, and Sarantis Livadas, and Anastasios Kollias, and Christos Adamopoulos, and Aikaterini Koulouri, and Charikleia Christakou, and Evanthia Diamanti-Kandarakis
January 2005, Clinical endocrinology,
Evangelia Tantalaki, and Christina Piperi, and Sarantis Livadas, and Anastasios Kollias, and Christos Adamopoulos, and Aikaterini Koulouri, and Charikleia Christakou, and Evanthia Diamanti-Kandarakis
November 2015, Metabolism: clinical and experimental,
Evangelia Tantalaki, and Christina Piperi, and Sarantis Livadas, and Anastasios Kollias, and Christos Adamopoulos, and Aikaterini Koulouri, and Charikleia Christakou, and Evanthia Diamanti-Kandarakis
June 2020, Obesity surgery,
Evangelia Tantalaki, and Christina Piperi, and Sarantis Livadas, and Anastasios Kollias, and Christos Adamopoulos, and Aikaterini Koulouri, and Charikleia Christakou, and Evanthia Diamanti-Kandarakis
January 2016, International journal of food sciences and nutrition,
Evangelia Tantalaki, and Christina Piperi, and Sarantis Livadas, and Anastasios Kollias, and Christos Adamopoulos, and Aikaterini Koulouri, and Charikleia Christakou, and Evanthia Diamanti-Kandarakis
January 2007, Clinical endocrinology,
Evangelia Tantalaki, and Christina Piperi, and Sarantis Livadas, and Anastasios Kollias, and Christos Adamopoulos, and Aikaterini Koulouri, and Charikleia Christakou, and Evanthia Diamanti-Kandarakis
December 2003, Biochemical Society transactions,
Evangelia Tantalaki, and Christina Piperi, and Sarantis Livadas, and Anastasios Kollias, and Christos Adamopoulos, and Aikaterini Koulouri, and Charikleia Christakou, and Evanthia Diamanti-Kandarakis
October 2009, Reproductive sciences (Thousand Oaks, Calif.),
Evangelia Tantalaki, and Christina Piperi, and Sarantis Livadas, and Anastasios Kollias, and Christos Adamopoulos, and Aikaterini Koulouri, and Charikleia Christakou, and Evanthia Diamanti-Kandarakis
January 2007, Metabolism: clinical and experimental,
Copied contents to your clipboard!